Antioxidants and cataracts
This article was originally published in The Tan Sheet
Executive Summary
Roche European American Cataract Trial (REACT) finds three-year daily use of antioxidant cocktail produces "small deceleration in progression of [age-related cataract]," Leo Chylack, MD, Brigham & Women's Hospital, Boston, et al., report in November Ophthalmic Epidemiology. Partly funded by Hoffmann-La Roche and Roche Vitamins, trial included 297 American and British early ARC patients randomly dosed with placebo or combinations of 18 mg beta carotene, 750 mg vitamin C, 600 mg vitamin E. Cataract severity was documented using serial digital retroillumination imagery, progression was measured as "increase % pixels opaque." Findings follow recent research showing antioxidants and zinc reduce risk of developing advanced age-related macular degeneration (1"The Tan Sheet" Oct. 15, p. 3)...
You may also be interested in...
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.